NCT06732492

RD13-02 Cell Injection in Patients with Relapsed or Refractory CD7-Positive Natural Killer/T Cell Malignancies

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Academic / Other
• Sex: All
• Age: 3 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, open-label, single-center, phase I study. The primary objective is to evaluate the safety of CD7 Chimeric Antigen Receptor-T(CAR-T) therapy for patients with CD7-positive relapsed or refractory natural killer/T cell lymphoma, and to evaluate the pharmacokinetics of CD7 CAR-T in patients。

Conditions

• NK T-Cell Lymphoma
• CART Therapy
• CD7-positive Relapsed/Refractory Lymphoid Hematologic Malignancies

Interventions

Type	Name	Description
DRUG	RD13-02 cell infusion	CAR-T cells

Timeline

• Start date: 2024-10-31
• Primary completion: 2026-12-31
• Completion: 2027-12-31
• First posted: 2024-12-13
• Last updated: 2024-12-13

Locations

1 site across 1 country: China